Astellas’ Gene Therapy Strategy Faces Fresh Setback as FDA Puts Pompe Disease Med on Hold

Astellas’ gene therapy ambitions have faced yet another setback. The FDA has slammed the breaks on a Phase I/II study of the Japanese pharma’s Pompe disease med while the regulator investigates a report of nerve damage in one of the trial’s participants.